Dragged by PhIII flop and shelved by AbbVie, a class of depression drugs finds new life at startup
A month before Allergan revealed that it would be bought out by AbbVie for $63 billion, CEO Brent Saunders took a painful hit on one of his own acquisitions: In the wake of successive Phase III flops for the key depression drug from its $560 million deal to buy Naurex, Allergan marked a $2.5 billion writedown.
So when AbbVie swallowed Allergan, it left rapastinel — and the next-generation NMDAR modulators that came after it — sitting on the shelves.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,600+ biopharma pros reading Endpoints daily — and it's free.